What emerges from the most recent first line trials is that the progress in advanced ovarian cancer depends not only on new treatment, but on the better patient selection: not all patients are in the…

Researchers at the Massachusetts Institute of Technology (MIT) developed a handheld system that gently collects living cells from patient samples to aid cancer testing and development of personalized ...

Neoadjuvant niraparib showed anti-tumour activity and enabled R0 resection in selected patients with HRD-positive advanced ovarian cancer who were initially unsuitable for primary debulking surgery. T...

Response rate to immune checkpoint blockade (ICB) in ovarian cancer remains low and combinatorial strategies are needed. Here the authors report the results of a phase I/II study of the PARP inhibitor...

Ovarian cancer remains a significant health concern for women in India, often diagnosed at advanced stages due to non-specific symptoms such as bloating, abdominal discomfort, changes in urinary habits, and loss of appetite. These symptoms are frequently overlooked as they resemble common issues like indigestion or hormonal changes. While blood tests, particularly CA-125, have been used for years as a marker for ovarian cancer, they are not reliable for early detection. CA-125 levels can rise due to non-cancerous conditions, and early-stage ovarian cancer may not elevate CA-125 levels, leading to false reassurance from normal test results. Researchers are exploring new biomarkers, including proteins and DNA fragments, and leveraging AI and machine learning to identify patterns that may indicate early cancer development. However, these methods are still in the research phase and have not yet met the rigorous standards required for routine screening in healthy populations. Current screening options for women at higher risk include CA-125 blood tests combined with ultrasounds, along with genetic testing for those with a family history of ovarian or breast cancer, especially before age 40 or 50. The article emphasizes that while promising, the research must be supported by strong evidence before these tests can become standard practice. The ultimate goal is to develop a reliable method that can detect ovarian cancer early, distinguish it from benign conditions, and save lives through timely intervention. The author, Dr. Abhilasha Narayan, a Senior Consultant in Gynaec Oncology at HCG Cancer Hospital, underscores the importance of ongoing research and the need for caution in labeling new tests as breakthroughs until they are proven effective.

15 January 2015 - 15 January 2026 #OctobreRose #PinkRibbonChallenge #HGSC #ovariancancer stage 1B #oncogenetics #BRCA1 From biology student to cancer patient 👩‍💻🎀 Thank you Massachusetts Institute o...

This study estimates the residual lifetime risk of ovarian cancer among BRCA carriers.

Dr. Heather Cheng, prostate cancer expert, discusses the PROMISE Study for prostate cancer patients.

YouTube video by Beverly L. Anderson